WO2014192682A1 - Agent d'activation contenant un cellobiose lipide en tant qu'ingrédient actif et agent favorisant la production de collagène - Google Patents

Agent d'activation contenant un cellobiose lipide en tant qu'ingrédient actif et agent favorisant la production de collagène Download PDF

Info

Publication number
WO2014192682A1
WO2014192682A1 PCT/JP2014/063808 JP2014063808W WO2014192682A1 WO 2014192682 A1 WO2014192682 A1 WO 2014192682A1 JP 2014063808 W JP2014063808 W JP 2014063808W WO 2014192682 A1 WO2014192682 A1 WO 2014192682A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
cell
activating agent
activation
cellobiose lipid
Prior art date
Application number
PCT/JP2014/063808
Other languages
English (en)
Japanese (ja)
Inventor
周子 山下
周平 山本
Original Assignee
東洋紡株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東洋紡株式会社 filed Critical 東洋紡株式会社
Publication of WO2014192682A1 publication Critical patent/WO2014192682A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • the present invention relates to an activator comprising cellobiose lipid as an active ingredient, and in particular, by activating various cells, it improves cell metabolism, regeneration and repair functions, and is effective in preventing aging and preventing hair growth and hair loss.
  • the present invention relates to cosmetics, quasi drugs, pharmaceuticals, and foods and drinks containing cellobiose lipid.
  • the present invention relates to a collagen production promoter, which is a cosmetic, quasi-drug, pharmaceutical, food and beverage containing a biosurfactant effective for anti-aging, skin texture adjustment, skin wrinkle prevention / control by collagen production. It is about goods.
  • the dermis and epidermis of the skin are composed of epidermal cells, fibroblasts, and extracellular matrices such as elastin, collagen, and hyaluronic acid that support these extracellular skin structures.
  • fibroblasts mainly control the synthesis and degradation of collagen and hyaluronic acid.
  • skin properties such as flexibility are ensured by maintaining the homeostasis of these skin tissue interactions, and the skin is glossy, tightened, transparent, and maintained moist. .
  • an activator derived from an animal system connective tissue hydrolyzate, thymus / spleen-derived water-soluble protein, bovine placenta extract and the like are known.
  • plant-derived activators include sesame seeds, sanjak, capsicum, touki, dokudami, bakumondo, almond, dandelion, elderberry, nematode, senburi, sakuhakuhi, tonin, carrot, hop, muguge, yokuinin, turmeric genus, An extract of the genus Hyanaseri is known. Some of these are used in quasi-drugs and cosmetics as activators and anti-aging agents, but their effects are not sufficient due to the large individual differences, and they exhibit satisfactory effects. No cell activation or anti-aging effect has been obtained.
  • Glycolipids are amphiphilic substances having both hydrophilic properties derived from the properties of sugars and lipophilic properties derived from the properties of lipids, and have a function as surfactants. There are various amphiphiles in the living body, and they are involved in the exchange of substances, energy, and information at various interfaces and play a major role in the formation of ecological order.
  • Non-Patent Document 1 cellobiose lipid (CL), which is a kind of glycolipid-based biological surfactant (biosurfactant), has been reported to show antifungal activity and has attracted attention.
  • Cellobiose lipid is known to be produced by Ustilago maydis (Ustyago Maydis) and Cryptococcus humicola (Cryptococcus Fumicola) (Non-patent Document 2).
  • Pseudozyma flocculosa Pseudozyma floculosa
  • Cellobiose lipid is industrially used in a wide range of fields such as detergents and cosmetics, and is used as a liposome-forming agent (see Patent Document 2), an emulsifier / solubilizer (see Patent Document 3), a protein separation carrier (patent) There are reports such as low molecular weight organogel (refer to Patent Document 5).
  • Cellobiose is highly biodegradable, has low toxicity, and is environmentally friendly. Therefore, it is expected to be put to practical use as a cosmetic and pharmaceutical material. However, at present, no effect on cell of cellobiosespirid has been found, and no effect or efficacy has been reported.
  • An object of the present invention is to provide an activator and an anti-aging agent that have excellent activation and anti-aging effects on cells and have safety sufficient to withstand long-term use, and cosmetics / pharmaceuticals comprising these as active ingredients To provide quasi-drugs, pharmaceuticals, and food and drinks.
  • this invention consists of the following structures.
  • a cell activating agent comprising cellobiose lipid.
  • 2. The cell activation agent according to 1, wherein the cell activation is activation of skin cells.
  • 3. The cell activation agent according to 1, wherein the cell activation is activation of fibroblasts, hair matrix cells, or hair papilla cells. 4).
  • 2. The cell activation agent according to 1, wherein the cell activation is promotion of collagen production.
  • 5. The cell activator according to any one of 1 to 4 above, which comprises cellobiose lipid having a structure represented by the following general formula (I) or (II).
  • R1 represents hydrogen or a hydroxyl group
  • n1 has 12 or 14 carbon atoms
  • R2, R3, and R4 of sugar 1 in formula I are an acetyl group or a hydroxyl group. Is shown.
  • R1 and R2 each represent hydrogen or a hydroxyl group.
  • N1 represents an alkylene group having 11 or 12 carbon atoms
  • n2 represents an alkylene group having 2 or 4 carbon atoms.
  • An anti-aging agent comprising the cell activator according to any one of 1 to 5 above. 7).
  • a skin protecting agent comprising the cell activating agent according to any one of 1 to 5 above.
  • a rough skin improving agent comprising the cell activating agent according to any one of 1 to 5 above.
  • a skin texture regulator comprising the cell activating agent according to any one of 1 to 5 above.
  • a skin wrinkle preventing / suppressing agent comprising the cell activating agent according to any one of 1 to 5 above.
  • the present invention it is possible to expect a cell activation action and collagen production action excellent in safety, and cosmetics and quasi-drugs (skin external preparations, bath preparations, hair restorers, etc.), pharmaceuticals, and foods and drinks containing cellobiose lipid as an active ingredient. Can be provided.
  • activation is intended to maintain or enhance cell function or cell activity. As a result, it is possible to help maintain cell function and cell activity homeostasis, and to suppress aging of cells. Therefore, “activator” is synonymous with “cell activator” and has utility as “anti-aging agent”.
  • activation, anti-aging in skin cells refers to skin wrinkles and sagging by reducing functional deterioration and metabolic abnormalities of skin cells that accompany the accumulation of structural changes in the underlying membrane due to aging and photoaging. This refers to the prevention and improvement of curing, etc., and maintaining the state of elasticity and youthful healthy skin.
  • the effects of external factors such as ultraviolet rays, significant air drying, excessive skin washing, stress, smoking, etc., and prevention of decreased fibroblast proliferation due to aging, skin elasticity or It refers to the reduction of elasticity, the prevention or improvement of skin wrinkles or sagging.
  • hair papilla cells or hair matrix cells it refers to the suppression of hair loss by maintaining the hair cycle by suppressing the functional decline of hair papilla cells or hair matrix cells due to aging, stress, hormone balance, etc. .
  • collagen production promotion refers to an effect of increasing the production amount of collagen produced by cells.
  • Collagen IV and VII are involved in the support and adhesion of epidermal cells at the boundary between the epidermis and dermis. Damage caused by aging and ultraviolet rays, especially collagen IV and VII, is reduced by ultraviolet rays, the epidermis and dermis support function is reduced, the selective permeation function is weakened, and harmful components easily affect the skin, thus generating wrinkles Is done.
  • the extracellular matrix that makes up the dermis is made from fibroblasts in the dermis, and is composed of fibrous proteins such as collagen and elastin and polysaccharides called acidic mucopolysaccharides such as hyaluronic acid. It is directly related to sex, metabolism and vitality. When the activity of fibroblasts is lowered, particularly from aging and photoaging, collagen biosynthesis is decreased and denatured elastin is increased.
  • Cellobiose lipid is a kind of glycolipid type biosurfactant having surface-active ability and emulsifying ability produced by living organisms.
  • Biosurfactant is a general term for substances having surface-active ability and emulsifying ability produced by living organisms, and not only exhibits excellent surface activity and high biodegradability, but also has various physiological functions. Therefore, there is a possibility of developing different behaviors and functions from synthetic surfactants.
  • Cellobiose lipid (hereinafter sometimes referred to as CL) has various variations in structure, and the difference in these molecular structures is based on the difference in producing microorganisms.
  • R1 represents hydrogen or a hydroxyl group
  • n1 represents 12-14.
  • R2, R3 and R4 of sugar 1 in formula (I) are acetyl groups or hydroxyl groups. These can be obtained as a mixture, but a single CL compound may be used after purification and separation.
  • R1 and R2 each represent hydrogen or a hydroxyl group.
  • n1 represents 11 to 12, and n2 represents 2 to 4. These can be obtained as a mixture, but may be used as a mixture even if a single CL compound is used after purification and separation.
  • Cellobiose lipid can be obtained by extracting and purifying a culture solution of cellobiose lipid-producing bacteria.
  • CL-producing bacteria include microorganisms belonging to the genus Cryptococcus and Ustilago and having the ability to produce cellobiose lipids.
  • Microorganisms of the genus Cryptococcus mainly produce cellobiose lipids of the above structural formula (I), and microorganisms of the genus Ustilago mainly produce cellobiose lipids of the structural formula (II).
  • the method for producing cellobiose lipid is not particularly limited, but a fermentation method using a known biosurfactant-producing microorganism may be arbitrarily selected.
  • cellobiose lipid can be cultured by culturing Cryptococcus humicola or Ustilago esculenta according to a conventional method.
  • Ustilago maydis, Pseudozyma flocculosa, Pseudozyma graminicola, and the like can be used.
  • the biosurfactant-producing microorganism is not particularly limited and can be appropriately selected depending on the purpose.
  • Fermentation media for producing cellobiose lipids include yeast extracts, N sources such as peptone, C sources such as glucose and fructose, and inorganic nitrogen sources such as sodium nitrate, dipotassium hydrogen phosphate, magnesium sulfate heptahydrate, etc.
  • a medium having a general composition composed of inorganic salts can be used.
  • Fermentation conditions such as pH and temperature, culture time, and the like can be arbitrarily set, and the culture solution after fermentation can be used as it is as the biosurfactant of the present invention.
  • any operation such as filtration, centrifugation, extraction, purification, sterilization and the like to the culture solution after fermentation, and the obtained extract can be diluted, concentrated and dried. .
  • the method for recovering and purifying cellobiose lipid can be appropriately selected according to the purpose.
  • it can be recovered by centrifuging the culture solution to recover the oil, and extracting and concentrating with an organic solvent such as ethyl acetate.
  • an extraction solvent use an organic solvent such as water, alcohols, ketones, diethyl ether, dioxane, acetonitrile, esters, xylene, benzene, chloroform, alone or in any combination of two or more kinds.
  • organic solvent such as water, alcohols, ketones, diethyl ether, dioxane, acetonitrile, esters, xylene, benzene, chloroform, alone or in any combination of two or more kinds.
  • a combination of the respective solvent extracts can also be used.
  • the extraction method There are no particular limitations on the extraction method, but usually it may be in the range of the boiling point of the solvent from room temperature to normal pressure.
  • After extraction it is filtered or adsorbed, decolored and purified using an ion exchange resin to form a solution. , Paste, gel, and powder. In many cases, it can be used as it is, but if necessary, further purification treatment such as deodorization and decolorization may be added as long as the effect is not affected.
  • a purification treatment means such as deodorization and decolorization, an activated carbon column or the like may be used, and a normal means generally applied depending on the extracted substance may be arbitrarily selected. If necessary, a cellobiose lipid with high purity can be obtained by purification using a silica gel column. *
  • the cellobiose lipid obtained as described above can be used as an activator as it is, it is preferably used by being blended in cosmetics, quasi drugs, pharmaceuticals, and foods.
  • the concentration of the cellobiose lipid is appropriately selected depending on the degree of absorption, the degree of action, the product form, the frequency of use, etc., and is not particularly limited, but is usually 0.00001 wt% to 0.1 wt%, preferably It is 0.0005 wt% to 0.05 wt%, more preferably 0.0001 wt% to 0.01 wt%.
  • cellobiose lipid can be used as an extract from a culture solution or as a purified high-purity product. Since cellobiose lipid is highly hydrophobic, it is preferably dissolved in a nonionic surfactant, lower alcohol or polyhydric alcohol. Alternatively, a sodium salt of cellobiose lipid that is easily dissolved in water may be used.
  • Fibroblasts are activated by using cellobiose lipid which is an active ingredient of the activator according to the present invention. Fibroblast activation normalizes epidermal cells and restores or restores skin barrier function and turnover, and is influenced by external factors such as ultraviolet rays, significant air drying, excessive skin washing, stress, and smoking. It is possible to prevent or improve a decrease in elasticity or elasticity of the skin due to aging, and to protect the skin from wrinkles or sagging of the skin.
  • Activation of fibroblasts can be promoted by using cellobiose lipid which is an active ingredient of the activator according to the present invention. With the activation of fibroblasts, the production of natural moisturizing factors such as hyaluronic acid is promoted, leading to improvement of rough and dry skin.
  • the activator according to the present invention is more preferably carried out in the form of a composition by blending cellobiose lipid, which is an active ingredient, into cosmetics, quasi drugs, pharmaceuticals, and foods.
  • cellobiose lipid which is an active ingredient for promoting collagen production according to the present invention
  • the ability to produce collagen is activated, the elasticity of the intercellular matrix is improved, and the texture is adjusted to a normal state.
  • the texture is adjusted, the light scattering effect is enhanced, and the dullness of the skin disappears and the skin tone becomes brighter.
  • “Skin Wrinkle Prevention / Inhibitor” refers to the effect of preventing wrinkle formation associated with aging and photoaging.
  • wrinkle is prevented and suppressed by promoting the ability of cells to produce collagen.
  • the generation of wrinkles is due to damage to the dermis cells accompanying irradiation of ultraviolet rays, destruction of the structure of the dermis composed of elastin and collagen due to the effects of aging, and a decrease in production thereof.
  • the dosage form is not limited and can be various such as ampules, capsules, powders, granules, pills, tablets, solids, liquids, gels, bubbles, emulsions, creams, ointments, sheets, mousses, bath preparations, etc. .
  • Cosmetics, quasi-drugs, and pharmaceuticals include, for example, basic and cosmetic preparations for internal and external use, lotions, emulsions, creams, ointments, lotions, oils, packs, facial cleansers and skin cleansers, shampoos, rinses, Hair treatments, hair creams, pomades, hair sprays, hair preparations, permanents, hair nickings, hair dyes, hair cosmetics such as hair growth and hair restorations, foundations, white powder, funny, lipstick, blusher, eye shadow, eyeliner, mascara Makeup cosmetics such as eyebrows and eyelashes, cosmetics for finishing such as beauty nails, perfumes, bath preparations, toothpastes, mouth fresheners, gargles, liquid odors and deodorants, sanitary products, sanitary cotton And wet tissue.
  • Examples of the food and drink include beverages such as soft drinks, carbonated drinks, nutrition drinks, fruit drinks, and lactic acid drinks, various forms of health nutrition supplements, health functional foods, tablets, capsules, drinks, troches, and the like. .
  • the activator according to the present invention is suitably applied to humans, but can also be applied to animals other than humans as long as each effect can be expected.
  • the activator according to the present invention includes ingredients used in cosmetics, quasi-drugs, pharmaceuticals, foods and drinks, as long as the effects of the present invention are not impaired as necessary. Additives can be used in combination.
  • Example 1 Production of cellobiose lipid (CL) using Cryptococcus humicola
  • Inoculum culture was performed by inoculating Cryptococcus humicola NBRC 10251 colonies into a seed medium (50 mL / 500 mL Sakaguchi flask) for 1 loop. Cultured overnight at 27 ° C. The obtained culture broth was used as an inoculum.
  • the seed medium composition was 10 g / L glucose, 3 g / L sodium nitrate, 0.5 g / L magnesium sulfate heptahydrate, 0.03 g / L sodium dihydrogen phosphate 0.1 g / L yeast extract.
  • the culture was carried out by inoculating 60 mL of the above-mentioned inoculum into 6 L (10 L-jar) of the production medium and using 10 L-jar under the conditions of 27 ° C., 530 rpm (stirring rotation), and 3 L / min (Air).
  • the composition of the production medium was 10 g / L glucose, 3 g / L sodium nitrate, 0.5 g / L magnesium sulfate heptahydrate, 0.03 g / L sodium dihydrogen phosphate 0.1 g / L yeast extract.
  • the culture solution cultured for 6 days was centrifuged (7500 rpm, 20 min) to separate the cells and the supernatant.
  • the precipitate was separated into a supernatant and the supernatant was dried with an evaporator to obtain a powder.
  • hexane 300 g was added and stirred, followed by glass filter filtration and evaporation to remove hexane. Thereby, a mixture of CL was obtained.
  • Example 2 Production of cellobiose lipid (CL) using Ustilago esculenta
  • Inoculum culture was performed by inoculating a colony of Ustilago esculenta NBRC 9887 into a seed medium (50 mL / 500 mL Sakaguchi flask) for 1 loop. Cultured overnight at 27 ° C. The obtained culture broth was used as an inoculum.
  • Seed medium composition is 50 g / L glucose, 3 g / L sodium nitrate, 0.5 g / L magnesium sulfate heptahydrate, 0.025 g / L potassium dihydrogen phosphate 0.5 g / L dipotassium hydrogen phosphate, 8 g / L L Yeast extract.
  • 100 mL of the above inoculum was inoculated into 6 L (10 L-jar) of the production medium, and cultured using 10 L-jar under the conditions of 27 ° C., 530 rpm (stirring rotation), and 3 L / min (Air).
  • Production medium composition is 50 g / L glucose, 3 g / L sodium nitrate, 0.5 g / L magnesium sulfate heptahydrate, 0.025 g / L potassium dihydrogen phosphate 0.5 g / L dipotassium hydrogen phosphate, 8 g / L Yeast extract.
  • the culture solution cultured for 6 days was centrifuged (7500 rpm, 20 min) to separate the cells and the supernatant.
  • the precipitate was separated into a supernatant and the supernatant was dried with an evaporator to obtain a powder.
  • hexane 300 g
  • glass filter filtration and evaporation were performed to remove hexane. Thereby, a mixture of CL was obtained.
  • Example 3 Na chloride of cellobiose lipid
  • Example 4 Structural analysis of cellobiose lipid
  • CLs obtained from Cryptococcus humicola and Ustilago esculenta were each identified by 1H-NMR measurement (proton nuclear magnetic resonance spectroscopy) at a resonance frequency of 500 MHz.
  • the measuring apparatus used was an NMR instrument AVANCE 500 manufactured by BRUKER, and deuterated chloroform (CDCl 3) and deuterated methanol (CD 3 OD) were used as solvents. As a result, it was found that all the powders obtained from these strains were CL.
  • Formulas 3 and 4 show general formulas.
  • Chemical formula 3 shows the main structure of CL derived from Cryptococcus humicola
  • chemical formula 4 shows the main structure of CL obtained from Ustilago esculenta.
  • R1 represents hydrogen or a hydroxyl group
  • n1 has 12 or 14 carbon atoms
  • R2, R3, and R4 of Sugar 1 in Formula I are an acetyl group or a hydroxyl group. Is shown.
  • R1 and R2 each represent hydrogen or a hydroxyl group.
  • N1 represents an alkylene group having 11 or 12 carbon atoms
  • n2 represents an alkylene group having 2 or 4 carbon atoms.
  • Example 5 Cell activation effect of cellobiose lipid using normal human skin fibroblasts
  • Normal human skin fibroblasts were seeded in a 48-well microplate so as to be 2.0 ⁇ 10 4 per well.
  • the seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum. After culturing at 37 ° C. in a carbon dioxide concentration of 5% for 24 hours, CL-Na salt was added to the test medium to a final concentration of 100 ⁇ g / mL to 1 ⁇ g / mL, and further cultured for 72 hours. Distilled water was provided as a solvent control.
  • DMEM Dulbecco's modified Eagle medium
  • the viable cell count measurement reagent SF was added and cultured for 3 hours, and the absorbance at 450 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
  • the evaluation results are shown in FIG. 1 as relative values with the cell activation effect in distilled water as 100.
  • CL-Na salt was added at a final concentration of 100 ⁇ g / mL to 10 ⁇ g / mL
  • human normal skin fibroblasts showed a higher cell activation effect than distilled water.
  • CL was added at a final concentration of 25 ⁇ g / mL
  • a significant cell activation effect of 30% or more than that of distilled water was observed. From this result, it is clear that CL has an excellent cell activating effect, and by applying CL to the skin, the metabolism and regeneration ability of skin cells are improved, and accordingly, the skin which is caused by aging, UV exposure, etc. It was suggested that wrinkles and sagging can be effectively improved.
  • Example 6 Evaluation of collagen production ability by CL-Na salt
  • the CL-Na salt powder described in Example 3 was dissolved in distilled water, and the final CL-Na salt concentrations were 100 ⁇ g / mL, 50 ⁇ g / mL, 25 ⁇ g / mL, 10 ⁇ g / mL, 5 ⁇ g / mL, respectively.
  • a cellobiose lipid aqueous solution of 1 ⁇ g / mL was prepared, and changes in collagen production in normal human skin fibroblasts were evaluated.
  • As a control only distilled water was used and evaluated in the same manner. The evaluation was performed according to the following procedure.
  • Normal human skin fibroblasts were seeded in a 48-well microplate so that the number of normal human skin fibroblasts was 1.0 ⁇ 10 4 per well.
  • the seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 1% fetal bovine serum. After culturing at 37 ° C. in a carbon dioxide concentration of 5 vol% for 24 hours, after washing twice with PBS ( ⁇ ), the medium was replaced with a serum-free medium to which a sample of any concentration was added, and the conditions were the same for 3 days and 6 days.
  • DMEM Dulbecco's modified Eagle medium
  • PBS PBS
  • type I procollagen C-terminal peptide Procollagen type I carboxyterminal propeptide: PIP
  • PIP Procollagen type I carboxyterminal propeptide
  • TaKaRa Procollagen type I C-peptide
  • the collagen production acceleration rate was determined by measuring a standard product with the above-mentioned ELISA kit, creating a calibration curve from the results, and obtaining the collagen production amount when the sample was added and the collagen production amount when no sample was added from the calibration curve.
  • Collagen is produced by fibroblasts.
  • the activation activity of fibroblasts by CL in FIG. 1 is 100 to 130%
  • the collagen production rate by CL in FIG. 2 shows an extremely high value of 160% to 260%. Therefore, this result shows that not only the ability to produce collagen was improved with the ability to activate fibroblasts by CL, but also that collagen production was promoted by the action of CL on any pathway in the metabolic system of collagen. Is suggested.
  • Example 7 Production example of serum
  • Composition (wt%) Citric acid 0.01 Na citrate 0.04 CL-Na salt 0.5 1.3. Butylene glycol 5.0 Concentrated glycerin 2.5 1.2. Pentanediol 2.0 Phenoxyethanol 0.25 Total amount of purified water is 100
  • Example 8 Production example of emulsion
  • An emulsion having the composition shown below was produced by a conventional method.
  • Composition (wt%) Glycerol ether 1.5 CL-Na salt 0.01 Sucrose fatty acid ester 1.5 Sorbitan monostearate 1.0 Squalane 7.5 Dipropylene glycol 5.0 Total amount of purified water is 100
  • Example 9 Production example of cream
  • a cream having the following composition was produced by a conventional method.
  • Composition (wt%) ⁇ -aminocaproic acid 0.2 CL-Na salt 0.1 Methyl paraoxybenzoate 0.5 Phenoxyethanol 0.2 1,3-butylene glycol 7.5 MEL 0.1 Cetanol 2.5 Behenyl alcohol 3.0 Squalane 5.0 Tri (caprylic / capric) glyceryl 15.0 Polyglyceryl pentastearate-10 0.95 Stearoyl lactate Na 0.3 Total amount of purified water is 100
  • Example 10 Production example of face wash
  • a face wash having the composition shown below was produced by a conventional method.
  • Composition (wt%) Edetate disodium 0.05 ⁇ -aminocaproic acid 0.2
  • Concentrated glycerin 1.5 CL-Na salt 0.1
  • Methyl paraoxybenzoate 0.15 1,3-butylene glycol 4.5
  • 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine (30% aqueous solution) 3.0
  • Phenoxyethanol 0.5 Total amount of purified water is 100
  • a biosurfactant-derived safety-enhanced cell activation effect, collagen production promoting effect, and anti-aging effect can be expected, and cosmetics and quasi-drugs containing these as active ingredients (skin external preparations, bath preparations, It is expected to make a significant contribution to the industry because it can provide hair restorers, food and drinks, and pharmaceuticals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)

Abstract

Le problème selon l'invention est de proposer un agent d'activation et un agent favorisant la production de collagène, possédant chacun un remarquable effet activateur et un remarquable effet anti-âge sur les cellules et ne présentant aucun danger même en cas d'utilisation à long terme ; et, également, un produit cosmétique, un produit quasi-pharmaceutique, un produit pharmaceutique, un aliment et une boisson, contenant chacun ledit agent d'activation ou ledit agent favorisant la production de collagène en tant qu'ingrédient actif. La solution selon l'invention consiste en un agent d'activation cellulaire caractérisé en ce qu'il contient un cellobiose lipide, c'est-à-dire un type de biotensioactif de nature glycolipidique.
PCT/JP2014/063808 2013-05-31 2014-05-26 Agent d'activation contenant un cellobiose lipide en tant qu'ingrédient actif et agent favorisant la production de collagène WO2014192682A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2013115292 2013-05-31
JP2013-115291 2013-05-31
JP2013-115292 2013-05-31
JP2013115291 2013-05-31

Publications (1)

Publication Number Publication Date
WO2014192682A1 true WO2014192682A1 (fr) 2014-12-04

Family

ID=51988714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/063808 WO2014192682A1 (fr) 2013-05-31 2014-05-26 Agent d'activation contenant un cellobiose lipide en tant qu'ingrédient actif et agent favorisant la production de collagène

Country Status (2)

Country Link
TW (1) TW201501727A (fr)
WO (1) WO2014192682A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3138613A1 (fr) * 2022-08-02 2024-02-09 Société la Biochimie Appliquée Composition cosmétique topique anti-âge comprenant de la flocculosine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060956A1 (fr) * 2005-11-25 2007-05-31 Toyo Boseki Kabushiki Kaisha Produit cosmétique de soin de la peau et agent servant à empêcher la peau de devenir rêche contenant des biotensioactifs
WO2008018448A1 (fr) * 2006-08-11 2008-02-14 Toyo Boseki Kabushiki Kaisha Activateur comprenant un bio-tensioactif comme ingrédient actif, un mannosyl érythritol lipide et son procédé de préparation
JP2009067758A (ja) * 2007-09-18 2009-04-02 Asahi Kasei Chemicals Corp 線維芽細胞賦活剤
JP2010158192A (ja) * 2009-01-07 2010-07-22 Sanwa Shurui Co Ltd 糖型バイオサーファクタント生産能を有する微生物及びそれを用いる糖型バイオサーファクタントの製造方法
JP2012176904A (ja) * 2011-02-25 2012-09-13 National Institute Of Advanced Industrial Science & Technology セロビオースリピッドを含有する低分子オルガノゲル
WO2013037977A2 (fr) * 2011-09-16 2013-03-21 Analyticon Discovery Gmbh Préparations cosmétiques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060956A1 (fr) * 2005-11-25 2007-05-31 Toyo Boseki Kabushiki Kaisha Produit cosmétique de soin de la peau et agent servant à empêcher la peau de devenir rêche contenant des biotensioactifs
WO2008018448A1 (fr) * 2006-08-11 2008-02-14 Toyo Boseki Kabushiki Kaisha Activateur comprenant un bio-tensioactif comme ingrédient actif, un mannosyl érythritol lipide et son procédé de préparation
JP2009067758A (ja) * 2007-09-18 2009-04-02 Asahi Kasei Chemicals Corp 線維芽細胞賦活剤
JP2010158192A (ja) * 2009-01-07 2010-07-22 Sanwa Shurui Co Ltd 糖型バイオサーファクタント生産能を有する微生物及びそれを用いる糖型バイオサーファクタントの製造方法
JP2012176904A (ja) * 2011-02-25 2012-09-13 National Institute Of Advanced Industrial Science & Technology セロビオースリピッドを含有する低分子オルガノゲル
WO2013037977A2 (fr) * 2011-09-16 2013-03-21 Analyticon Discovery Gmbh Préparations cosmétiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KULAKOVSKAYA, T. ET AL.: "Extracellular Cellobiose Lipid from Yeast and Their Analogues: Structures and Fungicidal Activities", JOURNAL OF OLEO SCIENCE, vol. 58, no. 3, 2009, pages 133 - 140 *
ROELANTS, S.L.K.W. ET AL.: "Biosurfactant gene clusters in eukaryotes: regulation and biotechological potential", APPLIED MICROBIOLOGY BIOTECHNOLOGY, vol. 98, 15 February 2014 (2014-02-15), pages 3449 - 3461, XP035328985, DOI: doi:10.1007/s00253-014-5547-4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3138613A1 (fr) * 2022-08-02 2024-02-09 Société la Biochimie Appliquée Composition cosmétique topique anti-âge comprenant de la flocculosine

Also Published As

Publication number Publication date
TW201501727A (zh) 2015-01-16

Similar Documents

Publication Publication Date Title
KR20150103138A (ko) 안티에이징용 피부 외용 조성물 및 그 제조방법
CN111278326A (zh) 改善皮肤、头发和头皮健康的基于酵母的面膜
JP5730837B2 (ja) メラニン生成抑制剤、保湿剤、美白化粧料、美容飲食品
WO2016157547A1 (fr) Composition topique pour la peau supprimant la transition à une inflammation
JP4939766B2 (ja) 基底膜安定化剤
WO2015114855A1 (fr) Utilisation d'un inhibiteur de kinésine contenant de la lutéoline ou son glucoside comme principe actif
KR101885195B1 (ko) 목서 발효추출물을 유효성분으로 함유하는 화장료 조성물
JP2017031185A (ja) キネシン抑制剤
JP6521210B2 (ja) セロビオースリピッドを含有することを特徴とするコラーゲン産生促進剤
KR101475505B1 (ko) 톳 추출물을 유효성분으로 함유하는 미백용 화장료 조성물
JP2009149566A (ja) バイオサーファクタントを含有する化粧品組成物
JP2009167159A (ja) バイオサーファクタントを含有する化粧品組成物
JP2016094439A (ja) 角質層を透明にする化粧料
JP4814509B2 (ja) ジアリールヘプタノイド誘導体を有効成分とするメラニン生成抑制剤と皮膚外用剤、飲食品への応用
JP2023171950A (ja) 抗老化剤、抗酸化剤、抗炎症剤、及び美白剤、並びに、化粧料
JP6521211B2 (ja) セロビオースリピッドを有効成分とする賦活化剤
JP6979919B2 (ja) ヒト正常細胞賦活剤
WO2014192682A1 (fr) Agent d'activation contenant un cellobiose lipide en tant qu'ingrédient actif et agent favorisant la production de collagène
JP2016190823A (ja) 神経成長因子抑制剤
JP2010150173A (ja) 美白剤、メラニン産生抑制剤、及び美白用皮膚外用剤
JP2010018559A (ja) バイオサーファクタントを含有する化粧品組成物
JP2009167158A (ja) バイオサーファクタントを含有する化粧品組成物
JP2009149567A (ja) バイオサーファクタントを含有する化粧品組成物
JP2009242310A (ja) インボルクリン産生促進剤、トランスグルタミナーゼ−１産生促進剤、ｅ−カドヘリン産生促進剤、及び毛穴目立ち軽減用皮膚外用剤
JP2004244327A (ja) 美白剤及び美白化粧料

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14803895

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14803895

Country of ref document: EP

Kind code of ref document: A1